Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16265316 | 0.89 | CYP3A4 (0.35) | SMN1; SMN2CYP1A2CYP3A4CYP2D6NPC1 | |
| SCHEMBL16265238 | 0.87 | CYP3A4 (0.36) | SMN1; SMN2CYP1A2CYP3A4CYP2D6NPC1 | |
| SCHEMBL21537293 | 0.86 | — | — | |
| SCHEMBL22299394 | 0.86 | RAB9A (0.41) | SMN1; SMN2CYP1A2CYP3A4CYP2D6NPC1 | |
| SCHEMBL19119557 | 0.85 | RARA (0.35) | SMN1; SMN2CYP1A2CYP3A4CYP2D6NPC1 | |
| SCHEMBL17694318 | 0.85 | CYP3A4 (0.33) | SMN1; SMN2CYP1A2CYP3A4CYP2D6NPC1 | |
| SCHEMBL20806068 | 0.84 | NR1H4 (0.36) | SMN1; SMN2NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL21537515 | 0.83 | APP (0.34) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17176869 | 0.83 | APP (0.33) | — | |
| SCHEMBL20647308 | 0.82 | SMN1; SMN2 (0.34) | SMN1; SMN2CYP1A2CYP3A4CYP2D6NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11015123-B2 | Liquid-crystal material | MERCK PATENT GMBH (DE) | 2021-05-25 | — | — | US | disclosed |
| US-20200255741-A1 | LIQUID-CRYSTAL MATERIAL | MERCK PATENT GMBH (DE) | 2020-08-13 | — | — | US | disclosed |
| EP-3458549-B1 | LIQUID-CRYSTAL MATERIAL | MERCK PATENT GMBH (DE) | 2020-07-22 | — | — | EP | disclosed |
| EP-3400270-B1 | DEVICE FOR REGULATING ENTRY OF LIGHT | MERCK PATENT GMBH (DE) | 2020-04-29 | — | — | EP | disclosed |
| US-10344217-B2 | Device for controlling the passage of energy, containing a dichroic dye compound | MERCK PATENT GMBH (DE) | 2019-07-09 | — | — | US | disclosed |
| US-10260001-B2 | Liquid crystal material | MERCK PATENT GMBH (DE) | 2019-04-16 | — | — | US | disclosed |
| EP-3004251-B1 | DEVICE FOR CONTROLLING THE PASSAGE OF ENERGY, CONTAINING A DICHROIC DYE COMPOUND | MERCK PATENT GMBH (DE) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017198637-A1 | LIQUID-CRYSTAL MATERIAL | MERCK PATENT GMBH (DE) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017118464-A1 | LIQUID-CRYSTALLINE MIXTURES | MERCK PATENT GMBH (DE) | 2017-07-13 | — | — | WO | disclosed |
| US-20170029702-A1 | LIQUID CRYSTAL MATERIAL | MERCK PATENT GMBH (DE) | 2017-02-02 | — | — | US | disclosed |
| US-20170029702-A1 | LIQUID CRYSTAL MATERIAL | MERCK PATENT GMBH (DE) | 2017-02-02 | — | — | US | disclosed |
| US-20160108317-A1 | DEVICE FOR CONTROLLING THE PASSAGE OF ENERGY, CONTAINING A DICHROIC DYE COMPOUND | MERCK PATENT GMBH (DE) | 2016-04-21 | — | — | US | disclosed |
| US-20160108317-A1 | DEVICE FOR CONTROLLING THE PASSAGE OF ENERGY, CONTAINING A DICHROIC DYE COMPOUND | MERCK PATENT GMBH (DE) | 2016-04-21 | — | — | US | disclosed |
| WO-2014187529-A1 | DEVICE FOR CONTROLLING THE PASSAGE OF ENERGY, CONTAINING A DICHROIC DYE COMPOUND | MERCK PATENT GMBH (DE) | 2014-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108317-A1 | DEVICE FOR CONTROLLING THE PASSAGE OF ENERGY, CONTAINING A DICHROIC DYE COMPOUND | CRY1, SLC25A1, CRY2 | SMN1; SMN2 3195/4885CYP1A2 2025/4885CYP3A4 1818/4885 |
| US-10344217-B2 | Device for controlling the passage of energy, containing a dichroic dye compound | CRY1, SLC25A1, CRY2 | SMN1; SMN2 3195/4885CYP1A2 2025/4885CYP3A4 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.